EORTC on the future of cancer research at ECCO 2017

World experts to discuss future methods in cancer research at EORTC ECCO workshop

Our workshop on the Future of Cancer Clinical Research & Therapy will bring together world experts Elizabeth Eisenhauer (Queen’s University, Canada), Stefan Sleijfer (Erasmus University, Netherlands) and Jorge Camarero (European Medicines Agency), to discuss “The regulatory and methodological dimensions of long term efficacy: PFS2 and looking beyond the first progression”.

This discussion will be followed by a session on “Registries and the external validity of clinical trials” with Gemma Gatta (Istituto Nazionale Tumori di Milano), Sabine Siesling (University of Twente, Netherlands) and Harlinde De Schutter (Belgian Cancer Registry).

Poster sessions

In addition, EORTC will be presenting two posters at the European Cancer Congress (ECCO 2017) in Amsterdam (January 27-30, 2017).

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data for Cancer Clinical Trials – SISAQOL consortium (Abstract 1333)

Session 226: Poster in the Spotlight II; Saturday 28.01.2017 – 4:00 PM – 5:00 PM
Location: Poster Area, Hall 1
Author: SISAQOL consortium

Update of the international prognostic classification for first line metastatic germ-cell cancers. An international initiative (Abstract 2197)

Session 255: Poster in the Spotlight IV; Sunday 29.01.2017 – 4:00 PM – 4:50 PM
Location: Poster Area, Hall 1
Author: L. Collette

Oral Presentations

Innovative methodology to optimise translation of trial outcome to real-world patients

Changing Practice Session: The Value of Cancer Registries; Sunday 29.01.2017 – 11:30 AM
Location: Room Zur Hausen
Speaker: L. Liu

Incorporating real-life data into drug development: towards more pragmatic trials

Changing Practice Session: External Validity of Clinical Trials; Monday 30.01.2017 – 10:35 AM
Location: Room Folkman
Speaker: M. Mauer


Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023